A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass

Curtin, 1994, Management of the adnexal mass, Gynecol. Oncol., 55, S42, 10.1006/gyno.1994.1340

Carney, 2002, A population-based study of patterns of care for ovarian cancer: who is seen by a gynecologic oncologist and who is not?, Gynecol. Oncol., 84, 36, 10.1006/gyno.2001.6460

McGowan, 1985, Misstaging of ovarian cancer, Obstet. Gynecol., 65, 568

Paulsen, 2006, Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals, Int. J. Gynecol. Cancer, 16, 11, 10.1111/j.1525-1438.2006.00319.x

Engelen, 2006, Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma, Cancer, 106, 589, 10.1002/cncr.21616

Earle, 2006, Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients, J. Natl. Cancer Inst., 98, 172, 10.1093/jnci/djj019

Giede, 2005, Who should operate on patients with ovarian cancer? An evidence-based review, Gynecol. Oncol., 99, 447, 10.1016/j.ygyno.2005.07.008

Maggino, 1994, Prospective multicenter study on CA 125 in postmenopausal pelvic masses, Gynecol. Oncol., 54, 117, 10.1006/gyno.1994.1179

Bast, 1983, A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer, N. Engl. J. Med., 309, 883, 10.1056/NEJM198310133091503

Jacobs, 1989, The CA 125 tumour-associated antigen: a review of the literature, Hum. Reprod., 4, 1, 10.1093/oxfordjournals.humrep.a136832

Moore, 2007, The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass, Gynecol. Oncol., 108, 402, 10.1016/j.ygyno.2007.10.017

Pickle, 2007, A new method of estimating United States and state-level cancer incidence counts for the current calendar year, CA Cancer J. Clin., 57, 30, 10.3322/canjclin.57.1.30

Hoskins, 1994, The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma, Am. J. Obstet. Gynecol., 170, 974, 10.1016/S0002-9378(94)70090-7

Bristow, 1999, Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer, Gynecol. Oncol., 72, 278, 10.1006/gyno.1998.5145

Curtin, 1997, Stage IV ovarian cancer: impact of surgical debulking, Gynecol. Oncol., 64, 9, 10.1006/gyno.1996.4550

Young, 1983, Staging laparotomy in early ovarian cancer, JAMA, 250, 3072, 10.1001/jama.1983.03340220040030

Olaitan, 2001, The surgical management of women with ovarian cancer in the south west of England, Br. J. Cancer, 85, 1824, 10.1054/bjoc.2001.2196

McGowan, 1985, Misstaging of ovarian cancer, Obstet. Gynecol., 65, 568

Bouchard, 2006, Proteins with whey-acidic-protein motifs and cancer, Lancet Oncol., 7, 167, 10.1016/S1470-2045(06)70579-4

Bingle, 2006, WFDC2 (HE4): a potential role in the innate immunity of the oral cavity and respiratory tract and the development of adenocarcinomas of the lung, Respir. Res., 7, 61, 10.1186/1465-9921-7-61

Drapkin, 2005, Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas, Cancer Res., 65, 2162, 10.1158/0008-5472.CAN-04-3924

Hellstrom, 2003, The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma, Cancer Res., 63, 3695

Jacobs, 1990, A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer, Br. J. Obstet. Gynaecol., 97, 922, 10.1111/j.1471-0528.1990.tb02448.x

Bailey, 2006, Risk of malignancy index for referral of ovarian cancer cases to a tertiary center: does it identify the correct cases?, Int. J. Gynecol. Cancer, 16, 30, 10.1111/j.1525-1438.2006.00468.x